Cancer
Breast cancer in Shanghai
上海 乳腺癌
19 hospitals in Shanghai
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 390 papers led
- 115 papers led
- 76 papers led
- 62 papers ledNo open trial led
- 50 papers ledNo open trial led
- 44 papers ledNo open trial led
- 44 papers led
- 43 papers ledNo open trial led
- 36 papers ledNo open trial led
- 28 papers ledNo open trial led
- 27 papers ledNo open trial led
- 26 papers ledNo open trial led
- 26 papers led
- 17 papers ledNo open trial led
- 10 papers led
- 10 papers ledNo open trial led
- 1 paper ledNo open trial led
- 1 paper led
- 0 papers led
Breast cancer in every city Shanghai on the disease page, with the national map
open trials on breast cancer with a hospital in Shanghai
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 135 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT06889610
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReal-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT06993506
Age 18 years to Not stated (registered criteria)
Led by National Cancer Center / Cancer Hospital, CAMS; 12 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Hefei, Shanghai, Shijiazhuang, Wuhan, Xiamen, Yantai, Zhengzhou
- RecruitingPhase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07235176
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07283692
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07347600
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Weifang, Wuhan, Xi'an, Xiamen, Yangzhou, Zhengzhou
- RecruitingA Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07349069
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingNeoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07383818
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an
- RecruitingNeoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07393425
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07396324
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingCDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon)
- Phase
- Phase 3
- Started
- 2026-04
- Posted
- Registry
- NCT07432178
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07441460
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingYL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07461454
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07471776
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07498478
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- RecruitingUltra-Hypofractionated vs Moderate Hypofractionated Radiotherapy for Regional Lymph Nodes in High Risk Breast Cancer
- Phase
- N/A
- Started
- 2026-04
- Posted
- Registry
- NCT07527689
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingArtificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07528716
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingDigital Mind-Body Therapy for Neoadjuvant Breast Cancer
- Phase
- N/A
- Started
- 2026-03
- Posted
- Registry
- NCT07541664
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07551050
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOpportunistic Breast Cancer Screening Using Non-Contrast Chest CT
- Phase
- Not given
- Started
- 2026-05
- Posted
- Registry
- NCT07557654
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07581795
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07591090
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSac-TMT Combined With Bevacizumab in TNBC With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07623577
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07638852
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer Study
- Phase
- Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07647016
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07647029
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07658183
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)
- Phase
- Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07729956
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07797218
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingResponse-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic Therapy
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07829848
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Recruiting1-Week Versus 3-Week PBI
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07832279
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingHypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based Reconstruction
- Phase
- N/A
- Started
- 2026-10
- Posted
- Registry
- NCT07835139
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingArtificial Intelligence (AI)-Based Personalized Exercise Coaching for Patients With Breast Cancer
- Phase
- N/A
- Started
- 2026-07
- Posted
- Registry
- NCT07844941
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingDalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06637150
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReverse HER2-negative Immune Resistant Breast Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06731140
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06756932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingHS-10502 Combination Treatment in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT06769425
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingCapecitabine in Low Risk Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06787339
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06793332
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06827236
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesBengbu, Changchun, Chengdu, Chongqing, Nanning, Shanghai, Xi'an
- RecruitingA Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06830889
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Shanghai
- RecruitingA Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06832202
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingJSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06846437
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer
- Phase
- N/A
- Started
- 2025-02
- Posted
- Registry
- NCT06856200
Age 18 years to Not stated (registered criteria)
Led by Cancer Hospital, Fudan UniversityShanghai
- RecruitingPhase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-02
- Posted
- Registry
- NCT06889688
Age 18 years to 70 years; women only (registered criteria)
Led by Sun Yat-sen Memorial Hospital; 4 listed hospitals as study sitesChangsha, Guangzhou, Guiyang, Shanghai, Wuhan
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06942234
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Real World Study of Sacituzumab Govitecan
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06966141
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06966700
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06977893
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou
- RecruitingA Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06992882
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPhase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT06993844
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesFuzhou, Guangzhou, Jinan, Shanghai
- RecruitingA Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07002177
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT07003074
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesChangchun, Changsha, Hefei, Jinan, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Tianjin, Urumqi, Wuhan
- RecruitingClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07008976
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Fuzhou, Haikou, Hefei, Lanzhou, Linyi, Nanchang, Nanchong, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Zhengzhou
- RecruitingA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07043725
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 52 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Harbin, Hefei, Hengyang, Jinan, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Taizhou, Tianjin, Urumqi, Weifang, Wenzhou, Wuhan, Xi'an, Xinxiang, Yantai, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingSC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07080619
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07100106
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Jinan, Nanning, Shanghai, Tianjin
- RecruitingA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07111832
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07117630
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07130383
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPhase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
- Phase
- Phase 1/Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07134153
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2025-10
- Posted
- Registry
- NCT07150208
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingT-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07152782
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-08
- Posted
- Registry
- NCT07156253
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07169994
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesAnyang, Chengdu, Fuzhou, Guangzhou, Harbin, Hefei, Luoyang, Meizhou, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Xiangyang
- RecruitingA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Phase
- Phase 3
- Started
- 2025-12
- Posted
- Registry
- NCT07174336
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Harbin, Shanghai, Shantou, Tianjin, Wuhan
- RecruitingAdjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07180056
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingContinuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07180082
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingIparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07180160
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingTrastuzumab Deruxtecan in Advanced Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07180264
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingSKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07182721
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07213791
Age 18 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingAn Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07222267
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen
- RecruitingNeoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07351487
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai
- RecruitingCorticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT07362914
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMulticenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07371208
Age 18 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingctDNA-guided Treatment Decision-making
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07394218
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAI-Enhanced Imaging in Population Breast Cancer Screening
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT07411443
Age 35 years to 69 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingLevel I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07469267
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan
- RecruitingRobustness Evaluation of Deep Inspiration Breath-Hold (DIBH) Plans in Internal Mammary Irradiation
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07498855
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingMolecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic Efficacy
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT07574749
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
- Phase
- Phase 4
- Started
- 2025-08
- Posted
- Registry
- NCT07578064
Age 18 years to 80 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
- Phase
- Phase 1/Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07612891
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2025-06
- Posted
- Registry
- NCT07653893
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingIntrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
- Phase
- Phase 4
- Started
- 2024-01
- Posted
- Registry
- NCT06230055
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingDalpiciclib in HR+/HER2- ABC
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06301438
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingDP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2024-03
- Posted
- Registry
- NCT06313086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Study of GC203 TIL in Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06375187
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingLM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06387628
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingclinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases
- Phase
- Not given
- Started
- 2024-03
- Posted
- Registry
- NCT06392217
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingBoost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06404697
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06439771
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06452706
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an
- RecruitingA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06465069
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Guangzhou, Shanghai
- RecruitingA Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06471205
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06492005
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06493864
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06500208
Age 18 years to 65 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2024-08
- Posted
- Registry
- NCT06503783
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHarbin, Shanghai
- RecruitingNeoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06516289
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06555068
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Recruiting68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06559371
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases
- Phase
- N/A
- Started
- 2024-12
- Posted
- Registry
- NCT06567353
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06611813
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou
- RecruitingAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06632886
Age 18 years to Not stated (registered criteria)
Led by Changhai HospitalShanghai
- RecruitingAll Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer:a Multi-center, Multi-cohort Phase II Trial
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06636981
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPlatform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06649331
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2024-11
- Posted
- Registry
- NCT06666270
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai, Zhengzhou
- RecruitingA Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06677879
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingNeoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06682195
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou
- RecruitingTarget-specific immunoPET Imaging of Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06715826
Age 18 years to 75 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingThe Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06718010
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06725940
Age 18 years to 65 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingQL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06786026
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSafety and Efficacy of IMPT or IMRT for Breast Cancer
- Phase
- Not given
- Started
- 2024-12
- Posted
- Registry
- NCT06826885
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingApplication of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer
- Phase
- N/A
- Started
- 2024-01
- Posted
- Registry
- NCT06911528
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of TYK-00540 Tablets in Patients With Advanced Solid Tumors
- Phase
- Phase 1/Phase 2
- Started
- 2024-01
- Posted
- Registry
- NCT06950086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingUltra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT07135661
Age 40 years to Not stated; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingctDNA in HER2+ EBC Neoadjuvant Treatment
- Phase
- Phase 2
- Started
- 2024-02
- Posted
- Registry
- NCT07335081
Age 18 years to 70 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Phase I Dose Escalation Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT07923214
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChengdu, Fuzhou, Shanghai
- RecruitingProphylactic Irradiation to the Contralateral Breast for BCAs Patients
- Phase
- N/A
- Started
- 2023-01
- Posted
- Registry
- NCT04960839
Age 30 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingA Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction
- Phase
- Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05692674
Age 18 years to 80 years; women only (registered criteria)
Led by Shanghai Proton and Heavy Ion CenterShanghai
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingFUSCC Refractory TNBC Platform Study (FUTURE2.0)
- Phase
- Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05749588
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05759546
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingFamitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05760378
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingCDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer
- Phase
- Not given
- Started
- 2023-04
- Posted
- Registry
- NCT05795335
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingPrecise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-04
- Posted
- Registry
- NCT05806060
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRC48-ADC in HER2-low Advanced Breast Cancer
- Phase
- N/A
- Started
- 2023-05
- Posted
- Registry
- NCT05831878
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingDisitamab Vedotin (RC48-ADC) in Breast Cancer
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05851677
Age not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingAdjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-06
- Posted
- Registry
- NCT05861271
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05862064
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingCapecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
- Phase
- N/A
- Started
- 2023-06
- Posted
- Registry
- NCT05876065
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingEC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05883852
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEfficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05891093
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT05891561
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingTCb vs EC-T in High Risk ER+/HER2- Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05901428
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05909332
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 13 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nantong, Ningbo, Shanghai, Shenyang, Xi'an, Yangzhou
- RecruitingContinuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05910398
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- RecruitingEfficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT05949541
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT05950945
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou
- RecruitingRegional Lymph Node Irradiation for High-risk pN0 Breast Cancer
- Phase
- N/A
- Started
- 2023-07
- Posted
- Registry
- NCT05976412
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
- Phase
- Phase 3
- Started
- 2023-08
- Posted
- Registry
- NCT05999149
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06042894
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2023-12
- Posted
- Registry
- NCT06120283
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Harbin, Nanchang, Shanghai, Shenyang
- RecruitingDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06178159
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT06227117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin
- RecruitingThe Efficacy of Compression/Ice Gloves/Socks in Patients With UTD1-induced Neuropathy.
- Phase
- N/A
- Started
- 2023-03
- Posted
- Registry
- NCT07638774
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingReverse Triple Negative Immune Resistant Breast Cancer
- Phase
- Phase 2
- Started
- 2022-06
- Posted
- Registry
- NCT05076682
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2022-10
- Posted
- Registry
- NCT05208762
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Shanghai
- RecruitingCTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
- Phase
- N/A
- Started
- 2022-09
- Posted
- Registry
- NCT05360290
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
- Phase
- Phase 1
- Started
- 2022-08
- Posted
- Registry
- NCT05470348
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingPatient-Reported Outcome and Safety Between Preoperative and Postmastectomy Radiotherapy in DIEP Flap Reconstruction
- Phase
- N/A
- Started
- 2022-08
- Posted
- Registry
- NCT05512286
Age 18 years to Not stated; women only (registered criteria)
Led by Huashan Hospital; 2 listed hospitals as study sitesChangsha, Shanghai, Zhengzhou
- RecruitingGQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2022-10
- Posted
- Registry
- NCT05575804
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Phase
- Phase 2
- Started
- 2022-11
- Posted
- Registry
- NCT05582499
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSNF Platform Study of HR+/ HER2-advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05594095
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingPre-operative Therapy in Breast Cancer
- Phase
- Not given
- Started
- 2022-11
- Posted
- Registry
- NCT05621564
Age 18 years to Not stated; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- RecruitingEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06551220
Age 18 years to 80 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai
- RecruitingEvaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer
- Phase
- N/A
- Started
- 2021-03
- Posted
- Registry
- NCT04517266
Age 18 years to 80 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingEffect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- Phase
- Phase 4
- Started
- 2021-06
- Posted
- Registry
- NCT04790305
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 26 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shijiazhuang, Suzhou, Wuhan, Xi'an, Yangzhou, Zhengzhou
- RecruitingSingle Arm Phase II Study of Fractionated Stereotatic Radiation Therapy (FSRT) for Bone Metastases in Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2021-01
- Posted
- Registry
- NCT04947280
Age not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Association Between Radiation Dermatitis and Skin Microbiome in Breast Cancer Patients
- Phase
- Not given
- Started
- 2021-01
- Posted
- Registry
- NCT05032768
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMedial vs. Entire Supraclavicular Lymph Node Radiation Therapy for Patients With Invasive Breast Cancer
- Phase
- Phase 3
- Started
- 2021-09
- Posted
- Registry
- NCT05059379
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of GC101 TIL in Advanced Breast Cancer (10hospital)
- Phase
- Early phase 1
- Started
- 2021-11
- Posted
- Registry
- NCT05142475
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingNeoadjuvant Radiation in Locally Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2021-03
- Posted
- Registry
- NCT05479409
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingApplication of CT-Linac-Based "All-in-One" One-Stop Radiotherapy in Breast Cancer
- Phase
- N/A
- Started
- 2021-08
- Posted
- Registry
- NCT07776301
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMarkers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
- Phase
- N/A
- Started
- 2020-04
- Posted
- Registry
- NCT04281641
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingHypofractionated Irradiation At Regional Nodal Area for Breast Cancer Vs Existed Standard Treatment
- Phase
- Phase 3
- Started
- 2019-02
- Posted
- Registry
- NCT03829553
Age 18 years to 75 years; women only (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingSentinel Node Biopsy Vs Observation After Axillary PET
- Phase
- N/A
- Started
- 2019-09
- Posted
- Registry
- NCT04072653
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingAdjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer
- Phase
- Phase 3
- Started
- 2019-12
- Posted
- Registry
- NCT04254263
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingHypofractionated Vs Conventional Fractionated Radiotherapy After Breast Conserving Surgery
- Phase
- N/A
- Started
- 2018-07
- Posted
- Registry
- NCT04025164
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 2 listed hospitals as study sitesDalian, Guiyang, Shanghai
- RecruitingAddition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
- Phase
- Phase 3
- Started
- 2017-07
- Posted
- Registry
- NCT03201861
Age 18 years to 70 years; women only (registered criteria)
Led by Renji HospitalShanghai
- RecruitingStereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors
- Phase
- Phase 2
- Started
- 2017-08
- Posted
- Registry
- NCT03392233
Age 18 years to 85 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
- Phase
- Phase 1
- Started
- 2013-01
- Posted
- Registry
- NCT02897700
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChangchun, Shanghai
- Not yet recruitingRe-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2027-01
- Posted
- Registry
- NCT07419880
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingJSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07336771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingHuaier Granule and Proteinuria
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07355361
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingFamitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07382687
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingNeoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07410559
Age 18 years to 75 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07419867
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07423611
Age 18 years to 70 years; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingStudy of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07466927
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingProton vs Photon IMRT Toxicity in Breast Cancer
- Phase
- Not given
- Started
- 2026-04
- Posted
- Registry
- NCT07537712
Age 18 years to Not stated; women only (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07556848
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingSac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07628504
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingRomiplostim N01 for Injection for Secondary Prophylaxis of CIT in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07771881
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast Cancer
- Phase
- N/A
- Started
- 2026-09
- Posted
- Registry
- NCT07782086
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Chengdu, Hefei, Luzhou, Nanjing, Shanghai, Xi'an, Xuzhou
- Not yet recruitingProtein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07825753
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07856303
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingRandomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huaier Granules
- Phase
- Phase 4
- Started
- 2025-09
- Posted
- Registry
- NCT05871437
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingHeterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06797622
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06798506
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingPatient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage
- Phase
- N/A
- Started
- 2025-06
- Posted
- Registry
- NCT06965556
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingChemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06996093
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
- Phase
- Phase 1
- Started
- 2025-06
- Posted
- Registry
- NCT07036185
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingStudy of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07088588
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingDe-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT07153757
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingSimple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07169864
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingNeoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06510465
Age 18 years to Not stated (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingT-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06548178
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06724263
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06731153
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Phase
- Phase 4
- Started
- 2023-10
- Posted
- Registry
- NCT05860907
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou
- Enrolling by invitationBreast Cancer PET/CT Imaging With 68Ga-pAKTi
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06943313
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
- Enrolling by invitationImmediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer Surgery
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07798466
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shanghai
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Cancer Hospital, Fudan University | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changhai Hospital海军军医大学第一附属医院(长海医院) | 2 | 221 open | 19 | 315 open | 201 open | 8812 open | 101 open | 7 | none | 2 | none | 1 | 1 | 0 | none | none | none | none | none | 9 | none | none | none | none | none | none | 01 open | none | none | none | none | 4 | 1 | 7 | none | 1 | none | 2 | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | 0 | 0 | 1 | none | 0 | none | none | none | none | |
| Changzheng Hospital海军军医大学第二附属医院(长征医院) | none | 3 | 151 open | 171 open | 40 | 41 open | none | 10 | none | none | 5 | 16 | 4 | 0 | 2 | 262 open | none | none | none | 6 | none | none | none | 1 | none | none | none | none | none | none | none | 5 | none | 8 | 1 | none | none | 2 | none | 0 | none | none | none | none | 1 | none | 5 | none | none | 2 | 1 | none | none | none | none | none | 1 | none | none | none | none | |
| Child Health Hospital | none | none | none | none | none | none | 26 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital, Fudan University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital of Fudan University复旦大学附属儿科医院 | none | none | none | none | none | none | none | 11 | 5 | 0 | 0 | 4 | none | 11 | 1 | none | 0 | none | 0 | 5 | 01 open | none | 1 | none | none | none | none | 1 | 2 | none | 213 open | 5 | 372 open | 3 | 1 | 0 | none | none | none | none | 3 | 11 open | 0 | 2 | 1 | 0 | 2 | 1 | none | 1 | none | 1 | 0 | 4 | 2 | none | 0 | none | 1 | 0 | none | |
| Dahua Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| East Hospital上海市东方医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院) | none | none | 2144 open | 6 | none | 7 | none | none | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院 | 324 open | none | none | none | none | none | none | none | none | 63 open | 0 | none | none | 51 open | none | none | none | none | none | 161 open | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | |
| Fengxian District Central Hospital上海市奉贤区中心医院 | none | 3 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院 | none | none | none | none | none | 2 | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Naval Medical University | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Rehabilitation Hospital, Tongji University上海市第一康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院 | 381 open | 328 open | 542 open | 8817 open | 24331 open | 21211 open | 39090 open | 15 | none | none | 3 | 6 | 0 | none | 4 | none | 0 | none | none | 3318 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Gongli Hospital上海市浦东新区公利医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gynecology Hospital, Fudan University复旦大学附属妇产科医院 | none | none | none | none | none | none | 17 | none | none | none | none | 0 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Huadong Hospital, Fudan University复旦大学附属华东医院 | none | 11 open | none | 41 open | 42 | 111 open | none | none | none | none | none | 0 | none | none | none | none | none | none | 0 | 6 | none | none | none | none | none | none | none | none | 2 | none | none | 14 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | 24 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huashan Hospital复旦大学附属华山医院 | none | 12 | 621 open | 226 open | 62 | 191 open | 261 open | 1226 open | none | none | 4 | 2 | 0 | 1 | 0 | 5 | none | none | none | 351 open | none | 1 | none | none | none | 231 open | 0 | 314 open | 17 | none | none | 5 | 3 | none | 1 | none | none | 7 | none | 10 | 11 | none | 1 | 1 | 1 | none | 6 | none | none | none | 0 | 0 | none | none | 2 | 1 | none | none | none | none | none | |
| Infant Hospital上海市第一妇婴保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiading District Anting Hospital上海市嘉定区安亭医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiahui International Hospital上海嘉会国际医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jing'an District Centre Hospital上海市静安区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jinshan Hospital, Fudan University复旦大学附属金山医院 | none | none | none | none | none | none | none | none | none | none | none | 5 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Longhua Hospital上海中医药大学附属龙华医院 | none | 7 | 11 | 13 | 44 | none | 36 | none | none | none | 1 | 4 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 51 open | none | 2 | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | 2 | 0 | none | none | none | none | 1 | none | none | none | none | |
| Minhang Hospital上海市闵行区中心医院 | none | none | none | 9 | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Putuo Hospital上海市普陀区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Renji Hospital上海交通大学医学院附属仁济医院 | 22 open | 81 open | 1045 open | 655 open | 883 open | 1037 open | 7620 open | 251 open | 3 | 1 | 1 | 3 | 10 | 2 | none | 242 open | none | none | 3 | 232 open | none | none | 1 | none | none | 111 open | 2 | 31 open | none | none | 3 | 11 | 10 | 0 | 2 | 0 | none | 0 | none | 3 | none | 1 | none | 0 | 2 | none | 6 | none | none | none | 171 open | 5 | none | none | none | 2 | none | none | none | none | none | |
| Ruijin Hospital上海交通大学医学院附属瑞金医院 | none | 221 open | 353 open | 9613 open | 6811 open | 11418 open | 11518 open | 14 | none | none | none | 131 open | 2 | 2 | 0 | 22 | 114 open | none | 2 | 9755 open | 0 | 5 | none | 0 | none | none | none | none | 2 | none | none | 594 open | 2 | 1 | 1 | none | none | 0 | 2 | 2 | 0 | 3 | none | none | none | 1 | 42 open | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | none | |
| Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Chest Hospital上海市胸科医院 | none | 4012 open | none | none | 41445 open | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 11 | 4 | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Children's Hospital上海市儿童医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 6 | 1 | none | 1 | none | 1 | none | 4 | 0 | none | none | none | none | none | none | none | none | 1 | none | 10 | 2 | none | none | none | none | none | none | none | none | none | 2 | 0 | 0 | 0 | 0 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | |
| Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心 | none | none | none | none | none | none | none | none | 171 open | none | none | 0 | none | 11 | 0 | none | 81 open | 5 | none | 11 | 0 | none | none | none | 2 | none | none | none | none | none | none | none | 971 open | 2 | none | none | none | none | none | none | 0 | 0 | 0 | 02 open | none | none | 3 | 0 | none | none | none | none | 2 | 2 | 1 | none | none | none | none | none | none | |
| Shanghai East Hospital, Tongji University同济大学附属东方医院 | 1 | 13 | 36 | 37 | 502 open | 12 | 50 | 13 | none | 0 | 1 | 2 | 2 | 2 | 1 | 13 | none | none | none | 7 | none | none | none | none | 1 | none | none | none | none | none | none | 201 open | 11 | none | none | none | none | 4 | none | 11 open | none | none | none | none | none | none | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Eighth People Hospital上海市第八人民医院 | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Electric Power Hospital上海电力医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fengxian District Central Hospital | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | 31 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai General Hospital上海市第一人民医院 | 5 | 3 | 361 open | 271 open | 494 open | 357 open | 62 | 13 | none | 1 | 5 | 24 | 2 | 0 | none | 2 | 0 | 0 | none | 118 open | none | 0 | none | none | none | none | none | none | none | none | none | 25 | 4 | none | 1 | 1 | none | 1 | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | |
| Shanghai Jiading Central Hospital上海市嘉定区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mengchao Cancer Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mental Health Center上海市精神卫生中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院 | none | none | none | none | 28 | none | none | none | none | none | none | 2 | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院 | 5 | 4 | none | none | 33 | 11 | 27 | 9 | none | 29 | none | 15 | 1 | 2 | none | none | none | none | none | 221 open | none | 1 | none | none | 1 | none | none | none | none | none | none | 15 | 0 | 2 | none | 0 | none | 4 | none | none | 0 | none | none | 1 | 1 | none | 0 | none | none | 1 | 0 | none | none | 0 | 1 | none | none | 1 | none | none | none | |
| Shanghai Proton and Heavy Ion Center上海市质子重离子医院 | 0 | none | 2 | none | 63 open | 01 open | 13 open | 2 | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong Hospital上海市浦东医院 | none | none | none | none | none | 2 | 10 | 6 | none | 0 | none | 0 | none | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pulmonary Hospital上海市肺科医院 | none | 5 | none | none | 39443 open | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 71 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Putuo District Liqun Hospital上海市普陀区利群医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Sixth People's Hospital上海市第六人民医院 | 3 | 0 | 27 | 21 | 43 | 15 | 43 | 8 | none | none | 0 | 35 | 0 | 4 | 1 | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | 11 | 2 | none | none | none | none | 2 | none | 4 | none | none | none | 0 | none | 0 | 0 | none | none | 7 | 1 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Shanghai Songjiang District Central Hospital上海市松江区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Stomatological Hospital上海市口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tenth People's Hospital上海市第十人民医院 | none | 3 | 27 | 21 | 61 | 14 | 44 | 12 | 3 | none | 0 | 21 | 0 | 2 | 0 | 5 | none | none | none | 10 | none | none | none | none | none | none | none | none | none | none | none | 27 | none | none | none | 2 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tong Ren Hospital上海市同仁医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Xuhui Central Hospital上海徐汇中心医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shibei Hospital上海市静安区市北医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shuguang Hospital上海中医药大学附属曙光医院 | none | none | 20 | none | none | none | none | none | none | none | none | 1 | none | 0 | 0 | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | 2 | none | none | none | 3 | none | none | none | none | none | none | none | none | 3 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Tongji Hospital同济大学附属同济医院 | none | 3 | none | 17 | 30 | none | none | 9 | none | none | none | 2 | 1 | 2 | none | 21 open | 01 open | 0 | none | 185 open | none | none | none | none | none | none | none | none | none | none | none | 9 | 2 | none | none | none | none | 2 | none | 0 | none | none | none | none | 0 | none | 0 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Xinhua Hospital上海交通大学医学院附属新华医院 | none | none | 21 | 24 | 32 | 12 | 28 | 32 | 1 | 5 | none | 4 | 0 | 17 | 0 | 2 | none | none | none | 7 | none | none | none | none | none | none | none | 2 | none | 2 | 9 | 7 | 363 open | 33 | 0 | none | none | 0 | none | 1 | 0 | 1 | 0 | 0 | 0 | 01 open | 2 | 21 open | 1 | 0 | 1 | 0 | 3 | 6 | 4 | none | none | none | none | none | none | |
| Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangpu Hospital上海市杨浦区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | |
| Zhabei Central Hospital上海市静安区闸北中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Hospital, Fudan University复旦大学附属中山医院 | 3 | 568 open | 40816 open | 1348 open | 1864 open | 779 open | 441 open | 19 | 3 | none | 0 | 5 | 28 | 0 | 2 | 234 open | none | none | none | 142 open | 1 | none | none | none | none | 0 | 4 | 11 open | none | none | none | 10914 open | 30 | none | 0 | 332 open | none | 3 | 1 | 3 | none | none | none | 1 | 2 | none | 4 | none | none | 1 | 0 | none | none | none | 1 | none | 0 | none | none | none | none | |
| Zhongshan-Xuhui Hospital上海市徐汇区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shanghai.
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 19
- Stomach cancer 315 open
- Lung cancer 201 open
- Pancreatic cancer 8812 open
- Breast cancer 101 open
- Glioma 7
- Retinoblastoma 2
- Osteosarcoma 1
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Lymphoma 9
- IgG4-related disease 01 open
- Coronary heart disease 4
- Congenital heart disease 1
- Scoliosis 7
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Behçet disease 1
- IgA nephropathy 1
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 151 open
- Stomach cancer 171 open
- Lung cancer 40
- Pancreatic cancer 41 open
- Glioma 10
- Chordoma 5
- Osteosarcoma 16
- Gastrointestinal stromal tumour 4
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 262 open
- Lymphoma 6
- Thrombotic thrombocytopenic purpura 1
- Coronary heart disease 5
- Scoliosis 8
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 1
- IgA nephropathy 5
- Osteogenesis imperfecta 2
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 1
- Glioma 11
- Hepatoblastoma 5
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 4
- Neuroblastoma 11
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 5
- Beta thalassaemia 01 open
- Atypical haemolytic uraemic syndrome 1
- Myasthenia gravis 1
- Moyamoya disease 2
- Biliary atresia 213 open
- Coronary heart disease 5
- Congenital heart disease 372 open
- Scoliosis 3
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 0
- Spinal muscular atrophy 3
- Fabry disease 11 open
- Pompe disease 0
- Duchenne muscular dystrophy 2
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 2
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 4
- Inherited epidermolysis bullosa 2
- Familial adenomatous polyposis 0
- Majeed syndrome 1
- NGLY1 deficiency 0
- Nasopharyngeal carcinoma 381 open
- Oesophageal squamous cell carcinoma 328 open
- Hepatocellular carcinoma 542 open
- Stomach cancer 8817 open
- Lung cancer 24331 open
- Pancreatic cancer 21211 open
- Breast cancer 39090 open
- Glioma 15
- Chordoma 3
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Ewing sarcoma 4
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 3318 open
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 11 open
- Stomach cancer 41 open
- Lung cancer 42
- Pancreatic cancer 111 open
- Osteosarcoma 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 6
- Moyamoya disease 2
- Coronary heart disease 14
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 0
- Behçet disease 24
- IgA nephropathy 1
- Congenital diaphragmatic hernia 1
- Oesophageal squamous cell carcinoma 12
- Hepatocellular carcinoma 621 open
- Stomach cancer 226 open
- Lung cancer 62
- Pancreatic cancer 191 open
- Breast cancer 261 open
- Glioma 1226 open
- Chordoma 4
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 351 open
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 231 open
- IgG4-related disease 0
- Myasthenia gravis 314 open
- Moyamoya disease 17
- Coronary heart disease 5
- Congenital heart disease 3
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 10
- Spinal muscular atrophy 11
- Pompe disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 6
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Inherited epidermolysis bullosa 2
- Hereditary angioedema 1
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 11
- Stomach cancer 13
- Lung cancer 44
- Breast cancer 36
- Chordoma 1
- Osteosarcoma 4
- Neuroblastoma 1
- Haemophilia A 1
- Coronary heart disease 51 open
- Scoliosis 2
- Idiopathic pulmonary fibrosis 1
- IgA nephropathy 1
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 0
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 22 open
- Oesophageal squamous cell carcinoma 81 open
- Hepatocellular carcinoma 1045 open
- Stomach cancer 655 open
- Lung cancer 883 open
- Pancreatic cancer 1037 open
- Breast cancer 7620 open
- Glioma 251 open
- Hepatoblastoma 3
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 10
- Neuroblastoma 2
- Multiple myeloma 242 open
- Haemophagocytic lymphohistiocytosis 3
- Lymphoma 232 open
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 111 open
- IgG4-related disease 2
- Myasthenia gravis 31 open
- Biliary atresia 3
- Coronary heart disease 11
- Congenital heart disease 10
- Scoliosis 0
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 3
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 2
- IgA nephropathy 6
- Primary biliary cholangitis 171 open
- Primary sclerosing cholangitis 5
- Hereditary angioedema 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 353 open
- Stomach cancer 9613 open
- Lung cancer 6811 open
- Pancreatic cancer 11418 open
- Breast cancer 11518 open
- Glioma 14
- Osteosarcoma 131 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 22
- B-cell acute lymphoblastic leukaemia 114 open
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 9755 open
- Beta thalassaemia 0
- Haemophilia A 5
- Thrombotic thrombocytopenic purpura 0
- Moyamoya disease 2
- Coronary heart disease 594 open
- Congenital heart disease 2
- Scoliosis 1
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 0
- Lymphangioleiomyomatosis 2
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Fabry disease 3
- Alport syndrome 1
- IgA nephropathy 42 open
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 2
- Osteosarcoma 1
- Neuroblastoma 6
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 1
- Beta thalassaemia 4
- Haemophilia A 0
- Biliary atresia 1
- Congenital heart disease 10
- Scoliosis 2
- Duchenne muscular dystrophy 2
- Behçet disease 0
- Alport syndrome 0
- IgA nephropathy 0
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hepatoblastoma 171 open
- Osteosarcoma 0
- Neuroblastoma 11
- Ewing sarcoma 0
- B-cell acute lymphoblastic leukaemia 81 open
- Aplastic anaemia 5
- Lymphoma 11
- Beta thalassaemia 0
- Fanconi anaemia 2
- Congenital heart disease 971 open
- Scoliosis 2
- Spinal muscular atrophy 0
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 02 open
- IgA nephropathy 3
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 13
- Hepatocellular carcinoma 36
- Stomach cancer 37
- Lung cancer 502 open
- Pancreatic cancer 12
- Breast cancer 50
- Glioma 13
- Retinoblastoma 0
- Chordoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 13
- Lymphoma 7
- Fanconi anaemia 1
- Coronary heart disease 201 open
- Congenital heart disease 11
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 11 open
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 361 open
- Stomach cancer 271 open
- Lung cancer 494 open
- Pancreatic cancer 357 open
- Breast cancer 62
- Glioma 13
- Retinoblastoma 1
- Chordoma 5
- Osteosarcoma 24
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 2
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 0
- Lymphoma 118 open
- Haemophilia A 0
- Coronary heart disease 25
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 4
- Lung cancer 33
- Pancreatic cancer 11
- Breast cancer 27
- Glioma 9
- Retinoblastoma 29
- Osteosarcoma 15
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Lymphoma 221 open
- Haemophilia A 1
- Fanconi anaemia 1
- Coronary heart disease 15
- Congenital heart disease 0
- Scoliosis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 4
- Spinal muscular atrophy 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 0
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 0
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 43
- Pancreatic cancer 15
- Breast cancer 43
- Glioma 8
- Chordoma 0
- Osteosarcoma 35
- Gastrointestinal stromal tumour 0
- Neuroblastoma 4
- Ewing sarcoma 1
- Multiple myeloma 1
- Neuromyelitis optica spectrum disorder 2
- Coronary heart disease 11
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 4
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 0
- Osteogenesis imperfecta 7
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 61
- Pancreatic cancer 14
- Breast cancer 44
- Glioma 12
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 21
- Gastrointestinal stromal tumour 0
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 10
- Coronary heart disease 27
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 2
- Oesophageal squamous cell carcinoma 3
- Stomach cancer 17
- Lung cancer 30
- Glioma 9
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 21 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 0
- Lymphoma 185 open
- Coronary heart disease 9
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 0
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Hepatocellular carcinoma 21
- Stomach cancer 24
- Lung cancer 32
- Pancreatic cancer 12
- Breast cancer 28
- Glioma 32
- Hepatoblastoma 1
- Retinoblastoma 5
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 17
- Ewing sarcoma 0
- Multiple myeloma 2
- Lymphoma 7
- Myasthenia gravis 2
- Wilson disease 2
- Biliary atresia 9
- Coronary heart disease 7
- Congenital heart disease 363 open
- Scoliosis 33
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Fabry disease 1
- Pompe disease 0
- Duchenne muscular dystrophy 0
- Behçet disease 0
- Alport syndrome 01 open
- IgA nephropathy 2
- Gaucher disease 21 open
- Niemann–Pick disease type C 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 3
- Hirschsprung disease 6
- Inherited epidermolysis bullosa 4
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 568 open
- Hepatocellular carcinoma 40816 open
- Stomach cancer 1348 open
- Lung cancer 1864 open
- Pancreatic cancer 779 open
- Breast cancer 441 open
- Glioma 19
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 5
- Gastrointestinal stromal tumour 28
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 234 open
- Lymphoma 142 open
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 0
- IgG4-related disease 4
- Myasthenia gravis 11 open
- Coronary heart disease 10914 open
- Congenital heart disease 30
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 332 open
- Idiopathic pulmonary fibrosis 3
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 3
- Duchenne muscular dystrophy 1
- Behçet disease 2
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.